SHC Stock Analysis: Buy, Sell, or Hold?
SHC - Sotera Health Company Common Stock
$18.12
-0.20 (-1.09%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 26, 2026
25d
Get Alerted When SHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SHC shows positive signals but monitor for confirmation. Market pricing in 1.3% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: SHC shows positive signals but monitor for confirmation. Market pricing in 1.3% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$25.89
Based on 8.0% avg growth
INTRINSIC VALUE TODAY
$16.07
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SHC is currently trading at $18.12, which is considered fair relative to its 30-day fair value range of $17.83 to $19.05. The stock's valuation (Forward PE: 19.5) is in line with its historical norms (18.8). At these levels, the market is pricing in 1.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is currently testing key support at $17.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.44 (+11.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is currently testing key support at $17.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.44 (+11.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$17.83 -
$19.05
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($20.44)
- NEUTRAL: Market pricing in 1.3% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$17.83 -
$19.05
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$17.85
Resistance Level
$19.39
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
19.51
Wall Street Target
$20.44
(+11.6%)
Revenue Growth (YoY)
9.1%
Earnings Growth (YoY)
183.3%
Profit Margin
4.8%
Valuation Premium vs History
+1.3% premium
PE vs Historical
19.5 vs 18.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.3%
(market-implied from PE analysis)
1-Year Target
$18.56
(+1%)
2-Year Target
$18.80
(+3%)
3-Year Target
$19.04
(+4%)
3-Yr Target (if PE normalizes)
(PE: 20→19)
PE COMPRESSION
$18.35
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 12.0%)
$29.41
(+61%)
Base:
(SPY PE: 19.5, Growth: 12.0%)
$25.74
(+41%)
Bear:
(PE: 16.6, Growth: 12.0%)
$21.88
(+19%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (20x PE) as earnings recover.
Forward PE: 20.53 | Forward EPS (Implied): $0.88
Bull Case
$21.88
(+21%)
Analyst growth 15.0%, PE expands to 21.6
Base Case
$18.12
(0%)
Market implied 0.0%, PE stable at 20.5
Bear Case
$13.86
(-24%)
Severe decline -15.0%, PE contracts to 18.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 31, 2026 11:20 AM ET
Data refreshes hourly during market hours. Next update: 12:20 PM
Data refreshes hourly during market hours. Next update: 12:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Gtcr Investment Xi Llc
SELL
8000000 shares
2025-09-05
Pincus & Co. Warburg
SELL
12000000 shares
2025-09-05
Michael P Rutz
SELL
126611 shares
2025-08-22
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$653 | 47 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 57 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$121 | 62 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$263 | 47 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$257 | 58 HOLD |
Advanced SHC Option Strategies
Professional options setups generated by AI based on today's SHC price and gamma walls.
